Oncology-Specific EHR Options

Article

By Cary A. Presant, MD, FACP1, Linda Bosserman, MD, FACP1, Wendy McNatt1, Brandon Emilio11Wilshire Oncology Medical Group, La Verne, California

Oncology-Specific EHR Options

By Cary A. Presant, MD, FACP1, Linda Bosserman, MD, FACP1, Wendy McNatt1, Brandon Emilio11Wilshire Oncology Medical Group, La Verne, California


To date, several different types of electronic health records (EHRs) have been useful in the medical oncology setting. Of the oncology-specific EHRs on the market, two-ARIA® (Varian) and MOSAIQ® (IMPAC)-are owned by radiation therapy equipment makers. Both have oncology modules that are highly detailed and integrated with their associated radiation therapy EHR. Both require servers for data, although practices interested in these EHRs could network to share servers, programming, and IT support.

Another oncology-specific EHR, the IKnowMed system used by US Oncology, is programmed centrally and standardized across all user practices. McKesson’s ASP-type EHR, Altos, has all the programmable entry options of Varian’s ARIA. Because Altos is an ASP model, the system does not require as much IT support onsite for servers and back-ups. Other EHR systems can be customized for medical oncology practice use; but-compared to oncology-specific systems that are updated for the growing number of oncology diagnoses, AJCC staging, and tumor features which correlate with therapies and outcomes-keeping a non–oncology-specific system up to date will require far more IT support. Several hospital systems, which do not have as many of the oncology capabilities as the Varian or IMPAC systems, could interface with an HL7 compliant system in a practice. (HL7 is the national standard for digital communication.)

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content